Navigation Links
Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
Date:1/26/2012

TARRYTOWN, N.Y., Jan. 26, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2011 financial and operating results on Thursday, February 16, 2012, before the U.S. financial markets open.  The Company will host a conference call at 8:30 AM EST that day.

Live audio of the conference call will be webcast online simultaneously.  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.  

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:   

 Manisha Narasimhan, Ph.D.

Peter DworkinInvestor Relations

Corporate Communications914-847-5126

914.847.764Manisha.narasimhan@regeneron.com

peter.dworkin@regeneron.com 


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
2. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
3. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
4. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
5. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
6. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
7. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
8. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
9. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
10. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
11. Regeneron Reports Second Quarter 2011 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, ... of Pharmaceutical Specialties, Inc. ("PSI").  The combination of ... Georgia -based PSI bring together both company,s clinical ... manufacturers, and payers an industry-leading specialty pharmacy. About ... , , ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global law ... 21st Drug & Medical Device Litigation Conference , taking place in New York Dec. ... chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the Trial ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with ... that works for them. When an inventor from Suisun City, Calif., was unsuccessful in ... share it with others. , He developed a prototype for PRO GO MASSAGE to ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a ... SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories ... and disposal. The new version is a faster and a more efficient product, ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):